The US Food and Drug Administration (USFDA) has given final approval to the US-based Zydus Pharmaceuticals, a subsidiary of Zydus Cadila to promote Ramipril capsules, in different potencies including 1.25 mg, 2.5 mg, 5 mg and 10 mg.
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, which is used for treating high blood pressure and congestive heart failure.
Moreover, it is a prodrug and is converted to the active metabolite ramiprilat by liver esterase enzymes.
Pharma Dynamics. The amount of deal is not disclosed by the company. It is the third acquisition by the company. Earlier in July, Lupin took over the German drug maker Hormosan Pharma and captured most of shares of Generic Health, Australia in August. 
after the banning of some of its products in the US market. It is recalled that the US Food and Drug Administration is not satisfied with the product quality of many of its drugs. It has, earlier banned 31 drugs in the US market. The Indian drug maker Ranbaxy is a major supplier of drugs to the US market. 
products of Indian medicine major, Ranbaxy do not conform to the safety standards set by the inspection agency of US. It has banned 31 drugs produced by Ranbaxy. The agency had not mentioned the name of Daiichi Sankyo, the Japanese firm which is in the process to buy the Indian medicine company in its report
produced by Ranbaxy. The agency has issued two letters to Indian drug major, warning it about the drug quality. The agency has raised questions on the quality of more than 30 generic drugs. The company is producing these drugs at its Paonta Sahib and Dewas plants.
